Evidence map›Paper›PMID 38631705›Full record

ArticleBMJ global health2024

Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans

Matti Marklund, Leopold N Aminde, Mary Njeri Wanjau, Boni M Ale, Adedayo E Ojo, Clementina E Okoro, Abimbola Adegboye, Liping Huang, J Lennert Veerman, Jason Hy Wu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matti MarklundDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden matti.marklund@pubcare.uu.se.ORCID http://orcid.org/0000-0002-3320-796X
Leopold N AmindeSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.ORCID http://orcid.org/0000-0003-2787-7518
Mary Njeri WanjauSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.
Boni M AleCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria.
Adedayo E OjoCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria.
Clementina E OkoroFederal Capital Territory Primary Health Care Board, Abuja, Nigeria.
Abimbola AdegboyeNational Agency for Food and Drug Administration and Control, Abuja, Federal Capital Territory, Nigeria.
Liping HuangFood Policy, The George Institute for Global Health, Newtown, New South Wales, Australia.
J Lennert VeermanSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.ORCID http://orcid.org/0000-0002-3206-8232
Jason Hy WuFood Policy, The George Institute for Global Health, Newtown, New South Wales, Australia.
Mark D HuffmanFood Policy, The George Institute for Global Health, Newtown, New South Wales, Australia.
Dike B OjjiCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria.

Funding

Evaluating the Implementation and Scale-Up of Nigeria National Sodium Reduction ProgramUG3HL152381 · NHLBI · UNIVERSITY OF ABUJA · PI HUFFMAN, MARK D, OJJI, DIKE BEVIS · 2020 to 2021
$1.2M
NHLBI NIH HHS UG3 HL152381
6 · The paper itself

Abstract

introductionNigeria is committed to reducing industrial

methodsThe effect on ischaemic heart disease (IHD) burden, costs and cost-effectiveness of a mandatory iTFA limit (≤2% of all fats) for foods in Nigeria were estimated using Markov cohort models. Data on demographics, IHD epidemiology and

resultsOver the first 10 years, a mandatory iTFA limit (assumed to eliminate iTFA intake) was estimated to prevent 9996 (95% uncertainty interval: 8870 to 11 118) IHD deaths and 66 569 (58 862 to 74 083) IHD events, and to save US$90 million (78 to 102) in healthcare costs. The corresponding lifetime estimates were 259 934 (228 736 to 290 191), 479 308 (95% UI 420 472 to 538 177) and 518 (450 to 587). Policy implementation costs were estimated at US$17 million (11 to 23) over the first 10 years, and US$26 million USD (19 to 33) over the population's lifetime. The intervention was estimated to be cost-saving, and findings were robust across several deterministic sensitivity analyses.

conclusionOur findings support mandating a limit of iTFAs as a cost-saving strategy to reduce the IHD burden in Nigeria.

Indexed as

Cost-Effectiveness AnalysisTrans Fatty AcidsCost-Benefit AnalysisHealth Care CostsHumansNigeriaTrans Fatty AcidsCardiovascular diseaseHealth economicsNutritionPublic Health

Identifiers

PMID38631705
PMCPMC11029410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.